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Abstract  31 
 32 
A systematic review and meta-analysis of available RCTs was conducted to evaluate the effect of 33 
zinc (Zn) intake on serum/plasma Zn status in infants. Out of 5500 studies identified through 34 
electronic searches and reference lists, 13 RCTs were selected after applying the 35 
exclusion/inclusion criteria. The influence of Zn intake on serum/plasma Zn concentration was 36 
considered in the overall meta-analysis. Other variables were also taken into account as possible 37 
effect modifiers: doses of Zn intake, intervention duration, nutritional status and risk of bias. 38 
RESULTS: The pooled β of status was 0.09 (CI 0.05 to 0.12). However, a substantial heterogeneity 39 
was present in the analyses (I²= 98%; p=0.00001). When we performed a meta-regression, the 40 
effect of Zn intake on serum/plasma Zn status changed depending on the duration of the 41 
intervention, the dose of supplementation and the nutritional situation (p ANCOVA= 0.054; <0.001 42 
and <0.007 respectively). After stratifying the sample according to the effect modifiers the results 43 
by duration of intervention showed a positive effect when Zn intake was provided during medium 44 
and long periods of time (4-20 weeks and >20 weeks). A positive effect was also seen when doses 45 
ranged from 8.1 to 12 mg/day. In all cases, the pooled β showed high evidence of heterogeneity. 46 
CONCLUSION: Zn supplementation increases serum/plasma Zn status in infants, although high 47 
evidence of heterogeneity was found. Further standardized research is urgently needed to reach 48 
evidence-based conclusions to clarify the role of Zn supplementation upon infant serum/plasma Zn 49 
status, particularly in Europe. 50 
 51 
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Introduction 66 
 67 
Zinc (Zn) is an essential nutrient, present in all body tissues and fluids. The biologic role of Zn is 68 
now recognized in the structure and function of proteins, including more than 300 enzymes, 69 
transcription factors, hormonal receptor sites, and biologic membranes. Zn has numerous central 70 
roles in DNA and RNA metabolism (MacDonald 2000), and it is involved in signal transduction, 71 
gene expression, and apoptosis. Zn enzymes are involved in nucleic acid metabolism and cellular 72 
proliferation, differentiation, and growth (Chesters 1978).                                                                                                     73 
Plasma Zn accounts for only about 0.1 per cent of the total body content. Zn has a rapid turnover, 74 
and its level appears to be under close homeostatic control. There is no ‘store’ for Zn in the 75 
conventional sense (Milne et al. 1983) and it is present in the body almost exclusively as Zn2+ 76 
bound to cellular proteins (Makonnen et al. 2003).                                                                                   77 
Assessment of the Zn nutriture of individuals is complicated by the fact that no generally accepted, 78 
sensitive and specific biomarker of serum/plasma Zn status exists (King 1990). Although it is true 79 
that serum/plasma Zn concentrations decrease within several weeks of the introduction of a diet 80 
containing a severely restricted amount of Zn (Baer et al. 1985), serum/plasma Zn concentrations 81 
are generally maintained within the normal range with small or moderate reductions in Zn intake. 82 
Moreover, factors unrelated to the level of Zn nutriture, such as recent meals, time of day, infection, 83 
tissue catabolism, and pregnancy, can also affect serum/plasma Zn concentrations (King 1990; 84 
Hambidge & Krebs 1995). Thus, the serum/plasma Zn concentration may not always be a reliable 85 
indicator of an individual’s true Zn status (Brown et al. 2002). Nevertheless a recent systematic 86 
review concluded that serum/plasma Zn concentration was responsive to both Zn supplementation 87 
and depletion and it remains the most widely used biomarker for Zn (Lowe et al. 2009). 88 
 89 
Infants have a relatively high requirement of Zn per unit body weight during a sensitive period of 90 
rapid growth and development (Hermoso et al. 2010). Recommendations for Zn intake during 91 
infancy vary widely across Europe, ranging from 1 mg/day up to 5 mg/day (Hermoso et al. 2010). 92 
The EURRECA project attempts to consolidate the basis for the definition of micronutrient 93 
requirements across Europe, taking into account relationships among intake, status and health 94 
outcomes, in order to harmonise these recommendations (Ashwell et al. 2008). This paper presents 95 
a systematic review of the data from all available randomized controlled trials (RCTs) meeting 96 
EURRECA’s quality standard (Matthys et al. 2011), which investigated Zn intake and biomarkers 97 
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of Zn status in infants, and combines these studies in meta-analyses to model Zn concentrations in 98 
serum or plasma as a function of Zn intake.  99 
 100 
Materials and Methods 101 
Search strategy 102 
 103 
This research was conducted within the framework of the European Micronutrient 104 
Recommendations Aligned (EURRECA) Network of Excellence that aims to identify the 105 
micronutrient requirements for optimal health in European populations (www.eurreca.org). This 106 
review was part of a wider review process to identify studies assessing the effect of Zn intake on 107 
different outcomes (biomarkers of Zn status and health outcomes). The wider searches were 108 
performed of literature published up to and including February 2010, and an updated search was 109 
carried out in January 2013. The databases MEDLINE, EMBASE and Cochrane using search terms 110 
for “study designs in humans” and “zinc” and “intake”. Both indexing and text terms were used and 111 
languages included were restricted to those spoken in the EURRECA Network (English, Dutch, 112 
French, German, Hungarian, Italian, Norwegian, Polish, Spanish, Greek, and Serbian.). The Ovid 113 
MEDLINE search strategy can be found in Table 1. Reference lists of retrieved articles and 114 
published literature reviews were also checked for relevant studies.  The procedure for the 115 
identification, selection of articles and data extraction is illustrated in Figure 1. 116 
Selection of articles 117 
Titles of articles identified from the searches were entered into an EndNote library. Papers were 118 
considered eligible for inclusion if they were RCTs, conducted in human infants (aged 0-12 119 
months), and studied the effect of supplements, fortified foods or micronutrient intake from natural 120 
food sources, and assessed Zn concentrations in serum / plasma. Zn intake was assessed from breast 121 
milk, infant formula and food sources (e.g. complementary foods), fortified foods (e.g. fortified 122 
formula or cereal) and supplements. 123 
Exclusion criteria applied were: studies conducted in animals; combined interventions e.g. >1 124 
micronutrient or micronutrient + lifestyle intervention which did not study the effect of the 125 
micronutrient separately; non primary studies (e.g. letters & narrative literature reviews); duplicate 126 
publications; studies where the Zn intake – status relationship was not reported or biomarkers of Zn 127 
other than serum / plasma Zn were used. 128 
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Briefly, titles and abstracts of the 10% of the library were screened in duplicate for eligibility by 129 
two reviewers and any discrepancies were discussed and resolved before screening the remaining 130 
references. Only when both reviewers agreed that titles and abstracts met the inclusion criteria were 131 
the articles included. When a title and abstract could not be included with certainty, the full text of 132 
the article was obtained and then further evaluated. The remaining 90% was distributed among the 133 
two reviewers in even parts. Following the initial screening process, full-text articles were obtained. 134 
Further inclusion and exclusion criteria were then applied. Papers were only included in the meta-135 
analysis if they were: randomised controlled trials; had an intervention duration of at least 2 weeks; 136 
and reported baseline data for all outcome measures. Non-randomised controlled trials, uncontrolled 137 
trials or trials reporting insufficient or unclear data were excluded. Data were extracted from each 138 
study and organized in a Microsoft Access database file (Microsoft Corp, Redmond, WA). 139 
 140 
Data synthesis  141 
When Zn status in serum/plasma was measured at different time points within the same population, 142 
we used the measures as different estimations (Bates et al. 1993; Makonnen et al. 2003 I/II). One 143 
study reported data from the total of infants included, between males and females separately, and 144 
according to age (<11 months and > 11 months) (Sazawal et al. 1996; 2004) and it was treated as 145 
five estimations within the meta-analysis. One study reported data from two groups of infants 146 
(stunted and non stunted) and these were treated as two different estimations (Umeta et al. 2000). 147 
One study reported data from two groups according to the form of Zn supplementation (tablets or 148 
liquid) and these were treated as two estimations within the meta analysis (Wessells  et al. 2012). Of 149 
the selected studies, two RCTs were companion papers (Makonnen et al. 2003 I; Sazawal et al. 150 
2004).  If dietary intake of Zn (in addition to the intervention) was not reported in the RCTs, we 151 
imputed a value of 1.3 mg/day, the mean dietary intake level of the RCTs that did report dietary Zn 152 
intake. As mean baseline serum/plasma Zn concentrations were infrequently reported in the RCTs, 153 
most of the RCTs assumed no differences in baseline serum/plasma Zn concentrations (n= 12). 154 
Only one study, Bates et al. 1993, failed to report anything regarding baseline serum /plasma Zn 155 
concentrations.  156 
 157 
Exposure and outcome and other covariates assessment: 158 
 159 
The influence of Zn intake on serum/plasma Zn concentrations was considered in the overall meta-160 
analysis. Other variables were also taken into account as possible effect modifiers. We considered 161 
doses of Zn intake (1 to 4 mg, 4.1 to 8 mg, 8.1 to 12 mg, and >12.1 mg), intervention duration (1 to 162 
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3 weeks, 4 to 20 weeks, and > 20 weeks), nutritional situation (healthy, nutritionally at risk, and 163 
poor nutritional status) and risk of bias (low, moderate or high).  164 
 165 
Assessment of nutritional situation in included studies 166 
 167 
Nutritionally at risk was defined as infants who lived in low income families with a low 168 
socioeconomic situation and poor nutritional status was defined as infants with protein energy 169 
malnutrition (PEM) but without congenital abnormalities or cerebral palsy or heart disease or 170 
infants with low birth weight during their first year. PEM occurs characteristically in children under 171 
5 years of age in circumstances where the diet is poor in protein, calories and micronutrients, and 172 
insufficient to satisfy the body's nutritional needs. It remains one of the most common causes of 173 
morbidity and mortality among children worldwide (WHO, 1999).  174 
 175 
Assessment of risk of bias in included studies 176 
Risk of bias was assessed in order to evaluate the quality of the studies included. The following 177 
indicators of internal validity specific to the RCT methodology were collected during data 178 
extraction: 1) method of sequence generation and 2) adequate allocation, 3) blinding, 4) number of 179 
participants at start, dropouts and dropout reasons, 5) outcome data complete, 6) funder adequate 7) 180 
other potential funding bias . Based on these indicators, two reviewers assessed the overall risk of 181 
bias. Disagreements were resolved by discussion. The criteria for judging these indicators were 182 
adapted from the Cochrane Handbook for Systematic Reviews (Higgins & Green 2009) (Table 2). 183 
 184 
Statistical analyses 185 
 186 
Mean and standard deviation (SD) or standard errors (SE) of the outcome (serum/plasma Zn) were 187 
assessed. From the mean and SD of each study beta values (β) and their SE were calculated because 188 
the statistical model that we used to estimate the relation between Zn intake (x-variable) and 189 
serum/plasma Zn (y- variable) is based on the assumption that this intake-serum/plasma Zn status 190 
curve is a logarithmic function and that both intake and serum/plasma Zn status follow a log-normal 191 
distribution (the natural logarithm of intake and serum/plasma Zn status have a normal distribution). 192 
Thus, the expected value of the serum/plasma Zn status score is expressed as: 193 
µy = β * µx + intercept, where µy represents the mean of the natural logarithm of the y–variable (= 194 
serum/plasma Zn status score), β represents the regression coefficient, and µx represents the mean 195 
of the natural logarithm of the x-variable (= Zn intake). The method used to systematically review 196 
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differences was a formal meta–analysis (Greenland 1998). A random-effects model was considered 197 
to be more appropriate than a fixed-effects model. We used the DerSimonian and Laird’s 198 
(DerSimonian & Laird 1986) to pool the estimates of betas across studies. Under this model, the 199 
pooled effect was the beta in the status parameter (serum / plasma), for an increment of 1 unit in Zn 200 
intake. A pooled beta estimate was calculated as a weighted average of the beta reported in each 201 
study. 202 
The formula we used to estimate the weighted effect size was (Hedges 1982): 203 
β pooled = ∑ βi wi  ⁄ ∑ wi 204 
where β pooled is the pooled estimate of the beta in status parameters; the weight (wi) of each study 205 
was computed as:  206 
wi = 1 / Vi + ح² 207 
where V is the variance of each study and   ح ²  is the inter study variance. 208 
Besides this, we calculated a 95% confidence interval for the pooled estimated of effect size:     209 
95% CI= β pooled ± (1.96 x SE pooled) 210 
where SE is the standard error of the pooled estimate (Greenland 1998). 211 
 212 
A test of heterogeneity was calculated, estimating Q statistics, which follows a chi-square 213 
distribution with degrees of freedom n-1, n being the number of studies included in the analysis. 214 
The I² Index measures the extent of the heterogeneity. A low P value for this statistic (lower than 215 
0.05) indicates the presence of heterogeneity, which somewhat compromises the validity of the 216 
pooled estimates (Takkouche et al. 1999). Because significant heterogeneity was clearly evident in 217 
the pooled beta estimates for all studies combined in each outcome, we evaluated potential sources 218 
of heterogeneity by linear meta-regressions (Greenland 1998). We fitted a meta-regression using the 219 
duration of the intervention, the doses of Zn intake, the risk of bias, and the nutritional situation as 220 
independent variables. The betas of the different status parameters according to Zn intake were used 221 
as the dependent variable.  Statistical differences in multivariate adjusted mean beta values between 222 
each possible heterogeneity sources were determined by ANCOVA.  Additionally we carried out 223 
additional meta-analyses by subgroups considering only those groups which provided significant 224 
values in the meta-regression.  Microsoft Excel Version (7.0), SPSS 10.0 for Windows and Review 225 
Manager 5.1, were used to conduct the statistical analyses. 226 
 227 
Results 228 
 229 
Five thousand five hundred articles were identified in the initial search strategy. After applying the 230 
exclusion / inclusion criteria, 344 articles from the search appeared to be potentially relevant. After 231 
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applying the additional eligibility criteria and grouping the studies by outcome, 9 randomized 232 
controlled trials (17 estimations) were selected (Walravens et al. 1989; Bates et al. 1993; Sazawal et 233 
al. 1996, 2004; Umeta et al. 2000; Osendarp et al. 2002; Lind et al. 2003; Makonnen  et al. 2003; 234 
Wasantwisut  et al. 2006; Chang et al 2010). The 2013 update of the original search identified 4 235 
additional articles (Berger et al. 2006; Mazariegos et al. 2010; Ba Lo et al.  2011; Wessells et al. 236 
2012), providing a total of 13 articles (22 estimates) for meta-analysis (Figure 1). 237 
 238 
Descriptive characteristics of the studies included in the meta-analysis are presented in Table 2. Of 239 
the 13 studies included, only six comply strictly with the age infants (0 to 12 months) (Umeta et al. 240 
2000; Osendarp et al. 2002; Lind et al. 2003; Berger et al. 2006; Wasantwisut et al. 2006; 241 
Mazariegos et al. 2010). The other seven studies included this age among their sample, but did not 242 
clarify how many are actually aged 0 to 12 months (Walravens et al. 1989; Bates et al. 1993; 243 
Sazawal et al. 1996, 2004; Makonnen et al. 2003; Chang et al 2010; Ba Lo et al. 2011; Wessells et 244 
al. 2012). None of the ages extended beyond 27 months, except Makonnen et al. 2003 which 245 
included children up to 5 years. Thus the age range of the studies included was from 3 weeks to 60 246 
months. 247 
 248 
Six studies were conducted in Asia, one in North America, one in Latin America and the Caribbean 249 
and five in Africa. The duration of the interventions ranged from 2 to 24 weeks. Doses of Zn intake 250 
ranged from 2.5 to 20 mg per day. The nutritional situation of infants also varied between studies: 251 
six studies were conducted in healthy infants (Bates et al. 1993; Umeta et al. 2000; Osendarp et al. 252 
2002; Lind et al. 2003; Wasantwisut et al. 2006; Wessells et al. 2012), six studies were conducted 253 
on infants who were nutritionally at risk (Walravens et al. 1989; Sazawal et al. 1996, 2004; Berger 254 
et al. 2006; Chang et al 2010; Mazariegos et al. 2010; Ba Lo et al. 2011;), and one study was 255 
conducted on infants with poor nutritional status (Makonnen et al. 2003).  256 
Table 3 summaries the internal validity of the included studies, assessed as described in the data 257 
synthesis section. The risk of bias was high in two studies (Bates et al. 1993; Umeta et al. 2000), 258 
five had a moderate risk (Sazawal et al. 1996; 2004; Osendarp et al. 2002; Makonnen et al. 2003; 259 
Berger et al. 2006; Wessells et al. 2012) and six had a low risk of bias (Walravens et al. 1989; Lind 260 
et al 2003; Wasantwisut et al. 2006; Chang et al 2010; Mazariegos et al. 2010; Ba Lo et al. 2011). 261 
 262 
In general, most of the studies found a significant and direct association between Zn intake and 263 
serum/plasma Zn status, with β values ranged from 0.031 and 0.233. Only four studies reported no 264 
statistically significant association between Zn intake and serum/plasma Zn status (Walravens et al. 265 
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1989; Bates et al. 1993; Makonnen et al. 2003; Wessells et al. 2012 (a) Tablets group). In order to 266 
summarize the results we performed a formal meta-analysis (Figure 2). 267 
 268 
Differences between serum/plasma Zn status measured according to the intervention group in each 269 
particular study and in the pooled analysis are shown in Figure 2. The pooled β was 0.09 (95%CI 270 
0.05, 0.12). However, a substantial heterogeneity was present in the analyses (I² for status = 98%). 271 
In order to investigate which variables may be potential effect modifiers, we performed a meta-272 
regression (Table 4). The effect of Zn intake on serum/plasma Zn status changed depending on the 273 
duration of the intervention, the dose of supplementation and the nutritional situation (p 274 
ANCOVA= 0.054; <0.001 and <0.007) respectively. After stratifying the sample according to the 275 
effect modifiers identified in the meta-regression (Table 5) the results by duration of intervention 276 
showed no significant effect when the duration was short (1 to 3 weeks) (β = 0.02; CI 95% -0.03 to 277 
0.07). Nevertheless, a positive effect was shown when Zn intake was provided over medium (4 to 278 
20 weeks)( β = 0.09; CI 95% 0.06 to 0.13) and long periods of time (>20 weeks) (β = 0.12; CI 95% 279 
0.07 to 0.16). However these pooled β still revealed high evidence of statistically significant 280 
heterogeneity (I²= 91 and 96 %) respectively. When doses of Zn ranged from 4.1 to 8 mg/day, there 281 
was no significant effect of Zn intake on the serum/plasma Zn; whereas a positive effect was seen 282 
when doses ranged from 8.1 to 12 mg/day (β = 0.12; CI 95% 0.09 to 0.16). For doses higher than 12 283 
mg/day we found no effect. However high evidence of heterogeneity was observed (I²= from 77 to 284 
96 %). When studies were categorised by nutritional situation, those studies based on healthy 285 
infants and on infants at nutritional risk reported a positive association between Zn intake and 286 
serum/plasma Zn status (β= 0.19; CI 95% 0.04 to 0.13 and β= 0.10; CI 95% 0.05 to 0.15) 287 
respectively. However, no association was found when the nutritional situation was poor (β= 0.05; 288 
CI 95% -0.02 to 0.12). Once again, the pooled β still showed high evidence of heterogeneity (I²= 289 
from 95 to 99 %).  Due to the high heterogeneity found in all the analyses, we decided to avoid 290 
calculating the dose-response relationship between Zn intake and serum/plasma Zn status. 291 
 292 
Discussion 293 
 294 
Our results indicate that Zn supplementation increases serum/plasma Zn status in infants, as 295 
suggested by most of the individual studies. However the results obtained in the meta-analyses were 296 
highly heterogeneous. Moreover, after carrying out several subgroup analyses, the pooled β for each 297 
sub analysis still showed high evidence of heterogeneity. We argue that conducting a meta-analysis 298 
with such data is important in order to highlight the differences between the results of the studies 299 
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available, rather than to present a unifying synthesis (Delgado-Rodríguez & Sillero Arenas in 300 
press). 301 
 302 
The interpretation of these results should be carefully considered for a number of reasons. First, the 303 
number of studies that were eligible for inclusion in this meta-analysis was small, which limited the 304 
statistical power of the analyses to examine the relation between status responses to Zn 305 
supplementation. Thus, the small effect size we found may be explained by the limited amount of 306 
available information.  Also, it is well acknowledged that when many statistical comparisons are 307 
carried out, one or more might reach significance due to chance alone (Bland & Altman 1995). It is 308 
also important to consider the scientific quality of included studies. Although meta-analyses are 309 
increasingly used to consolidate results from multiple studies of the same topic and to develop 310 
evidence-based policies for clinical practice and public health programmes, the reliability of 311 
reached conclusions depend on the methodological quality of the original studies, the 312 
appropriateness of the study inclusion criteria, and the thoroughness of the review and synthesis of 313 
information (Brown et al. 2002). While strict systematic review protocols were followed adhering 314 
to EURRECA’s quality standards (Matthys et al 2011), an assessment of the risk of bias of included 315 
studies revealed that the majority (n=7) had a high to moderate risk of bias.  316 
 317 
Positive effects of Zn supplementation on mean serum Zn concentrations have also been reported in 318 
previous meta-analyses conducted in children, pregnant women and adults (Brown et al. 2002; Hess 319 
et al. 2007; Hall Moran et al 2012a, Hall Moran et al 2012b; Lowe et al 2012). In these meta-320 
analyses, there was a significantly positive effect of Zn supplementation over the mean serum Zn 321 
concentrations of the studied population. However, to our knowledge, meta-analytical methods have 322 
not yet been used to model serum/plasma Zn status as a function of Zn intake levels in infants. 323 
Understanding the relationship between dietary intake and micronutrient status is essential for 324 
deriving dietary recommendations. 325 
 326 
Population mean concentration of serum Zn is a useful indicator of the successful delivery and 327 
absorption of Zn supplements in infants. Both serum and plasma Zn concentrations are the most 328 
widely used biochemical indicators of serum/plasma Zn status but their levels are not necessarily 329 
identical. For instance, several biochemical studies designed to compare plasma and serum Zn 330 
concentrations observed higher levels of Zn in serum than in plasma (Kasperek et al. 1981; English 331 
& Hambidge 1988). These differences may have occurred because serum samples were separated 332 
from blood cells after a longer period of time than plasma samples, so more Zn went out from the 333 
cells into serum than into plasma. By controlling both, the amount of blood collected and the time 334 
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of cell separation, no differences were found in the Zn concentrations of serum and plasma (English 335 
& Hambidge 1988). For the sake of simplicity, this paper referred to “serum/plasma Zn” without 336 
making any distinction between them.  337 
 338 
Some confounders should be considered in evaluating the effect of Zn intake on infant 339 
serum/plasma Zn status. Those confounders include low birth weight, breastfeeding, protein energy 340 
malnutrition, poverty and social deprivation. The pre-existing serum/plasma Zn status of the study 341 
subjects, the content and bioavailability of Zn in the local diets, and the incidence of common 342 
infections that can affect individual’s serum/plasma Zn status are others important confounders to 343 
take into account. Moreover, methodological aspects of these studies, such as variations in the dose, 344 
chemical form, method of administration of Zn and duration of supplementation, may have 345 
influenced their results (Brown et al. 2002). However, with the exception of Bates et al (1993), all 346 
the RCTs included in the meta-analysis assumed no baseline differences in serum/plasma Zn. As all 347 
the studies included in our meta-analysis are RCTs we may assume that the randomization has been 348 
correct and these factors should not bias the results. 349 
 350 
Age of the study populations considered in this meta-analysis was another important point. We 351 
believe that there was no reason to exclude any study that did not adhere exclusively to the group of 352 
0 to 12 months of age. For this reason, we took into account all the studies which included this age 353 
group in the study, even if they were not analysed according to their age group (Walravens et al. 354 
1989; Bates et al. 1993; Makonnen et al. 2003; Sazawal et al. 2004, 1996; Chang et al. 2010; Ba Lo 355 
et al. 2011; Wessells et al. 2012) and assumed the consequences of this possible bias. Another 356 
confounding factor that might explain the inconsistency in our findings is that serum Zn 357 
concentrations vary according to the time of day, proximity of previously consumed meals, and 358 
occurrence of recent physical activity or other forms of stress, fluctuating by as much as 20% 359 
during a 24-hour period (Hambidge et al. 1989). The diurnal variation in circulating Zn 360 
concentration is largely a result of metabolic changes after meal consumption, although some 361 
variation may occur as a result of normal circadian variation in metabolism (Guillard et al. 1979; 362 
Wallock et al. 1993). Meal consumption results in a decrease in serum/plasma Zn concentrations, 363 
which add up following repeated meals (Goode 1991; Wallock et al. 1993), whereas overnight and 364 
daytime fasting result in increased circulating Zn concentrations (Wallock et al. 1993).  Of the 365 
studies included in our meta-analyses, those conducted by Walravens et al. 1989, Umeta et al. 2000, 366 
Osendarp et al. 2002, Berger et al. 2006, Wasantwisut et al. 2006, Ba lo et al. 2011 and Wessells et 367 
al. 2012 reported the time of the day when the blood samples were collected (during the morning). 368 
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Due to small numbers it was not possible to conduct a subgroup analysis on the time of the day that 369 
the samples were collected. 370 
 371 
Infection and inflammation can decrease serum/plasma Zn values, with the magnitude of change 372 
depending on the severity and stage of infection (Brown 1998). In community- based surveys, the 373 
reductions in serum/plasma Zn concentration due to infection average ~10% to 12% compared with 374 
healthy reference groups (Thurnham et al. 2005). Several other factors, such as low serum albumin, 375 
elevated white blood cell counts, use of hormones, can also affect serum/plasma Zn levels and must 376 
be considered in the interpretation of laboratory results (IZiNCG 2004). In our meta-analysis, all 377 
studies accounted for the presence of disease over the duration of the intervention and whether or 378 
not Zn levels were affected by that.  379 
 380 
Infants suffering from protein-energy malnutrition have low concentrations of Zn in serum/plasma, 381 
muscle and liver (Hansen & Lehman 1969; Cheek et al. 1970). Because Zn is needed for tissue 382 
synthesis during nutritional rehabilitation, the amount required may exceed dietary supply (Castillo-383 
Duran et al. 1987; Gibson et al. 1998). Makonnen et al 2003 were the only authors in our meta-384 
analysis which included infants with PEM. In this study, improvement in serum/plasma Zn status 385 
became evident only after 60 days. In children with PEM it takes over one month for serum levels 386 
to increase significantly, so this could explain the limited effect Zn supplementation had on 387 
serum/plasma Zn levels at 30 days. Inclusion of a study conducted in malnourished children might 388 
have contributed to the lack of significance in the present meta-analysis.  Finally, most of the 389 
studies were carried out among low-income populations of Asia and Africa and some of them were 390 
based on nutritionally at risk subjects so the generalization of the reported estimations to European 391 
populations could be compromised. 392 
 393 
In conclusion, a positive significant association was found between Zn intake and serum/plasma Zn 394 
status in infants. The magnitude of effect we found was in all cases rather small.  Based on this 395 
limited group of studies and their heterogeneity, we found insufficient current information to 396 
suggest that supplementation of Zn has a positive effect on infants’ serum/plasma Zn status or to 397 
recommend mean serum/plasma Zn concentration of a given population as a useful predictor of 398 
response to Zn supplementation. Further standardized research is urgently needed to reach 399 
evidence-based conclusions to clarify the role of Zn supplementation upon infant serum/plasma Zn 400 
status, particularly in Europe and other affluent societies. 401 
 402 
 403 
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Figure 1: Flow diagram for the systematic review. 
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Figure 2: Forest Plot of RCTs evaluating the effect of zinc intake on serum/plasma zinc    
                   status in infants 
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Table 1: Search strategy: MEDLINE February 2010  
 
(MEDLINE  home page. Available online: http://www.ncbi.nlm.nih.gov/pubmed/) 
No.  Search term 
 
Results 
1 randomized controlled trial.pt. 280,821 
  
2 controlled clinical trial.pt. 79,998  
 
3 randomised.ab. 196,604  
 
4 placebo.ab. 117,891  
 
5 clinical trials as topic.sh. 146,242  
 
6 randomly.ab. 145,491  
 
7 trial.ab. 203,467  
 
8 randomised.ab. 38,423  
 
9 6 or 3 or 7 or 2 or 8 or 1 or 4 or 5 734,511  
 
10 (animals not (human and animals)).sh. 4,482,479  
 
11 9 not 10 642,665  
 
12 (cohort* or ''case control*'' or cross-sectional* or ''cross sectional'' or case-control* or prospective or ''systematic 
review*'').mp. 
768,885  
 
 
13 exp meta-analysis/ or expmulticenter study/ or follow-up studies/ or prospective studies/ or intervention studies/ 
or epidemiologic studies/ or case-control studies/ or exp cohort studies/ or longitudinal studies/ or cross-
sectional studies/ 
1,013,635 
 
  
 
14 13 or 12 1,203,767  
   
15 14 not 10 1,154,385  
 
16 11 or 15 1,599,094 
  
17 ((zinc or zn or zinc sulphate or zinc gluconate or zinc acetate or methionine or zinc isotope*) adj3 (intake* or 
diet* or supplement* or deplet* or status or serum or plasma or leukocyte or concentration* or expos* or fortif* 
or urine or hair)).ti,ab. 
16,681 
 
 
 
18 Nutritional Support/ or Dietary Supplements/ or nutritional requirements/ or Breast feeding/ or exp infant food/ 
or bottle feeding/ or infant formula/ 
63,098  
 
 
19 exp Nutritional Status/ or exp Deficiency Diseases/ or supplementation/ or diet supplementation/ or dietary 
intake/ or exp diet restriction/ or exp mineral intake/ or Diet/ or Food, Fortified/ or nutrition assessment/ or 
Nutritive Value/ 
176,014  
 
 
 
20 (intake* or diet* or supplement* or deplet* or status or serum or plasma or leukocyte or concentration* or 
expos* or fortif* or urine or hair).ti,ab. 
3,166,092  
 
 
21 18 or 19 or 20 3,263,114  
 
22 zinc/ 41,027  
 
23 22 and 21 20,745  
 
24 23 or 17 26,943  
 
25 24 and 16 2410  
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Table 2:  Characteristics of the 13 (22 estimations) Status studies included in the meta-analysis 
Author Study 
year 
Country Sample 
Age range or Mean (SD) 
Number of 
Infants (n) 
Doses of Zinc/ 
day 
Time of the 
intervention 
Outcome 
(measure) 
Nutritional situation Risk of bias ² 
   Zn ¹ C¹ 
Ba Lo 2011 Senegal 9 to 17 months 33 32 6 mg 15 days Status (plasma) Nutritionally at risk Low risk 
   Bates   (a)        
               (b)                                                
1993 Gambia 5.7 to 27 months 30         
46 
28            
44 
20 mg 2 weeks               
8  weeks 
Status (plasma) Healthy  High risk 
Berger 2006 Vietnam 4 to 7 month 161 155 10 mg 24  weeks Status (serum) Nutritionally at risk Moderate  risk 
Chang 2010 Bangladesh 6 to 18 months 85 89 2,5 mg 24  weeks Status (serum) Nutritionally at risk Low risk 
Lind 2003 Indonesia 6.1 (0.5) months 134 143 10 mg 24  weeks Status (serum) Healthy Low risk 
                       (a) 
  Makonnen (b) 
                     (c) 
2003 Lesotho 6 to 60 months 142 
141 
138 
121 
119 
116 
10 mg         4  weeks 
8  weeks 
12 weeks 
Status (serum) Poor nutritional status Moderate  risk 
Mazariegos 
 
2010 Guatemala 6 to 12 months 24 29 5 mg 24  weeks Status (plasma) Nutritionally at risk Low risk 
Osendarp 2002 Bangladesh 3 to 5 weeks 138 133 5 mg 20  weeks Status (serum) Healthy  Moderate  risk 
   Sazawal   (a) 
                      (b) 
                    (c) 
                    (d) 
                    (e) 
1996- 
2004³ 
India 6 to 35 months 
6 to 11 months 
> 11 months 
Females 
Males 
223 
78 
69 
115 
108 
224 
78 
73 
106 
118 
10 mg 16  weeks 
 
Status (plasma) Nutritionally at risk Moderate  risk 
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 (a - e): Estimations                                                                                                                                                                                                                                                                                                                                                                 
¹Zn: Zinc group / ¹C: Control group                                                                                                                                                                                                                                                                                                                                                  
² Low risk of bias meant that the study was randomized, the randomization method was at least partially described, reasons for and numbers of dropouts were stated (or there were no dropouts), and the 
method used to assess compliance and some assessment of compliance were reported. All others studies were considered as moderate when they meet any of the above criteria or high risk of bias when they 
meet any of the criteria. (Higgins 2009, Cochrane Handbook)                                                                                                                                                                                                                                                                           
³Companion paper 
 
              (a) 
       Umeta 
             (b) 
2000 Ethiopia Zinc stunted                  9.5 (2.0) mo 
Placebo stunted           9.7 (2.0) mo  
Zinc non stunted           9.3 (2.1) mo  
Placebo non stunted    9.2 (2.0) mo 
25 
 
25 
25 
 
25 
8,57 mg  24  weeks 
 
Status (serum) 
 
Healthy  
 
High risk 
Walravens 1989 USA 8 to 27 months 16 25 5,7 mg         24  weeks Status (plasma) Nutritionally at risk Low risk 
Wasantwisut 2006 Thailand 4 to 6 months 58 66 10 mg 24  weeks Status (serum) Healthy  Low risk 
Wessells  
         (a)Tablets 
(b)Liquid 
2012 Burkina 
Faso 
6 to 23 month  
149        
146 
150 5 mg 3 weeks Status (plasma) Healthy Moderate  risk 
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Table 3: Assessment of internal validity in RCTs of serum/plasma Zn status. 
 
 
 
Author, Year 
Method of 
sequence 
generation 
Adequate 
allocation 
Blinding adequate 
Number at start, 
dropouts & 
dropouts reasons 
Outcome data 
complete 
Funder adequate  
Others potential 
funding bias 
 
Overall risk of 
bias 
 
Ba Lo 2011 
Bates  1993 
Berger 2006 
Chang 2010 
Lind  2003 
Makonnen  2003 
Mazariegos 2010 
Osendarp  2002 
Sazawal  1996-2004 
Umeta 2000 
Walravens 1989 
Wasantwisut  2006 
Wessells 2012 
 
Yes 
Yes 
Unclear 
Yes 
Yes 
Yes 
Yes 
Unclear 
Unclear 
Unclear 
Yes 
Yes 
Yes 
 
Yes 
No 
Unclear 
Yes 
Yes 
Unclear 
Yes 
Unclear 
Unclear 
Unclear 
Unclear 
Yes 
Yes 
 
Yes 
Unclear 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Unclear 
Yes 
Unclear 
Unclear 
Yes 
Yes 
Yes 
 
Yes 
No 
Yes 
Yes 
Yes 
Unclear 
Yes 
Yes 
Yes 
Unclear 
Yes 
Yes 
Yes 
 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
 
Low risk 
High risk 
Moderate risk 
Low risk 
Low risk 
Moderate risk 
Low risk 
Moderate risk 
Moderate risk 
High risk 
Low risk 
Low risk 
Moderate risk 
 
Page 23 of 25 Maternal & Child Nutrition
For Peer Review
Table 4:  Meta-regression. Multivariate adjusted mean beta for Status (95% confidence interval) by different characteristics of the  
                studies included in the meta-analysis 
 
 
 n  Mean Beta’s CI (95%) P Ancova* 
Status     
By duration of the intervention     
1 to 3 weeks 4 0.0221            -0.0752  to  0.1194  
4 to 20 weeks 10 0.0543 0.0142  to 0.0943  
> 20 weeks 8                      0.1331 0.0805  to 0.1858  
    0.054 
By Dose     
1 to 4 mg 1 -0.1025 -0.2081 to 0.0031  
4,1 to 8 mg 6 0.1893  0.1021 to 0.2764  
8,1 to 12 mg  13 0.1070  0.0650 to 0.1491  
> 12 mg 2 0.0855  0.0215 to 0.1495  
    <0.001 
By Nutritional situation     
Healthy 9 0.0456  0.0048 to 0.0863  
Nutritionally at risk 10 0.1184  0.0686 to 0.1681  
Poor nutritional situation 3 0.0456  0.0048 to 0.0863  
    <0.007 
By Risk of Bias     
Low 6 0.0978 0.0351 to 0.1606  
Moderate 12 0.0558 0.0140 to 0.0976  
High 4 0.0558 0.0140 to 0.0976  
    0.255 
 
* Adjusted for the rest of variables in the table 
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Table 5: Pooled beta (95% confidence intervals) in Status according to the intervention group.  
               Subgroup analyses. 
 
 
 
 Pooled estimates (β) Chi² (df, P) I² 
Status    
All Studies (n=22 ) 0.09 (0.05 to 0.12) 1166.30 (21,  < 0.00001) 98% 
By duration of the intervention    
1 to 3 weeks (n=4)   0.02 (-0.03 to 0.07) 31.78 (3,  < 0.00001) 91% 
4 to 20 weeks (n=10) 0.09 (0.06 to 0.13) 141.21 (9,   < 0.00001) 94% 
> 20 weeks (n=8)   0.12 (0.07 to 0.16) 162.64 (7,   < 0.00001) 96% 
By dose    
1 to 4 mg (n=1)  0.04 (0.01 to 0.07)   
4,1 to 8 mg (n=6)   0.04 (-0.01 to 0.09) 22.08  (5,   0.0005) 77% 
8,1 to 12 mg (n=13) 0.12 (0.09 to 0.16) 341.12  (12,   < 0.00001) 96% 
> 12 mg (n=2) 0.02 (-0.01 to 0.05) 7.21 (1,   0.007) 86% 
By Nutritional Situation    
Healthy (n=9) 0.09 (0.04 to 0.13) 220.90 (8,   < 0.00001) 96% 
Nutritionally at risk (n=10) 0.10 (0.05 to 0.15)  615.54 (9,   < 0.00001) 99% 
Poor nutritional status (n=3)  0.05 (-0.02 to 0.12)  39.26 (2,   < 0.00001) 95% 
 
*I² Index measures the extent of the heterogeneity 
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